Replies to post #804487 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I’ll interject. The mia certification updates we learned about mid December, that delay likely caused by the need to satisfy new July 2025 regulations, serendipitously gave NWBO time to mature the remaining ten year data if/when they supply their submission to NICE, being that ten year data from last randomized patient accrued in November 2025. I wouldn’t be shocked if the legislation was also worked on by people like Lowdell, Powers, etc.

It does provide another barrier to entry, and a blueprint for the future.

Regardless, here we are.

[SkyLimit2022]

High-Ranking Officer e❌,

That is a “funny thing” 🤔 ..And it’s actually pretty insightful! Manufacturing is the “best possible explanation” for delay of the MAA, but it also explains the delay of industry buy-in for DC technologies overall. STANDARDIZED AUTOMATION is beginning to change that & COMBO research is fueling the motivation to speed production capabilities!

Good job, Dennis & ex!


Two Keys:
🔑 Targeted COMBOS
🔑 Scalable MANUFACTURING






Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.

Dr. Kalinski



NWBO’s IP portfolio includes more than one pipeline product in active clinical development. For example, the aDC1 platform that NWBO licensed from Roswell Park in New York has reached PII in combo with Merck’s pembrolizumab. NEXT GEN COMBOS will make some significant waves going forward!



Next Generation Dendritic Cell Treatments




Pitt BioForge

NWBO Acquires Advent BioServices

Roswell Park Dendritic Cell Technology & IP

Fud Flood 🌊

[brooktrail1933]

He's not.
But we know you work for them.